FibroBiologics, Inc. Common Stock
- Open
- 0.94
- Day high
- 0.94
- Day low
- 0.92
- Prev close
- 0.95
- Volume
- 18K
- Mkt cap
- $5M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 1.9
- P/S
- —
- Yield
- —
- Per share
- —
FibroBiologics, Inc. Common Stock (FBLG) is a Healthcare company listed on NASDAQ. The stock is down 94% over the past year.
FibroBiologics, Inc. Common Stock (FBLG) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 2 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
FBLG earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Apr 30, 2026 | $-1.26 | $-1.33 | -5.6% | — | — |
| Feb 24, 2026 | $-0.09 | $-0.03 | +66.7% | — | — |
| Oct 31, 2025 | $-0.10 | $-0.13 | -30.0% | — | — |
| Jul 31, 2025 | $-0.11 | $-0.12 | -9.1% | — | — |
| Mar 31, 2025 | $-0.10 | $-0.09 | +10.0% | — | — |
| Dec 30, 2023 | — | $-0.34 | — | — | — |
| Jun 29, 2023 | — | $-0.07 | — | — | — |
| Jun 30, 2022 | — | $-0.04 | — | — | — |
| Mar 31, 2022 | — | $-0.04 | — | — | — |
FBLG insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 23, 2026 | Hoffman Robert E.director | Grant | 30,803 | $0.75 |
| Jun 23, 2026 | Niklas Victoria Ninon Oliviadirector | Grant | 30,803 | $0.75 |
| Jun 23, 2026 | Link Matthewdirector | Grant | 30,803 | $0.75 |
| Jun 23, 2026 | Cilento Richard C. Jr.director | Grant | 30,803 | $0.75 |
| May 4, 2026 | Khoja Hamidofficer: Chief Scientific Officer | Grant | 61,607 | $1.38 |
| May 4, 2026 | GARCIA RUBEN Aofficer: General Counsel | Grant | 61,607 | $1.38 |
| May 4, 2026 | Davis Jasonofficer: Chief Financial Officer | Grant | 61,607 | $1.38 |
| May 4, 2026 | O'HEERON PETEdirector, officer: CHIEF EXECUTIVE OFFICER | Grant | 92,410 | $1.38 |
| Mar 5, 2026 | Khoja Hamidofficer: Chief Scientific Officer | Buy | 30,000 | $0.38 |
| Mar 4, 2026 | O'HEERON PETEdirector, officer: CHIEF EXECUTIVE OFFICER | Buy | 15,872 | $0.38 |
| Mar 4, 2026 | O'HEERON PETEdirector, officer: CHIEF EXECUTIVE OFFICER | Buy | 17,428 | $0.35 |
| Mar 4, 2026 | O'HEERON PETEdirector, officer: CHIEF EXECUTIVE OFFICER | Buy | 18,200 | $0.41 |
| Mar 2, 2026 | GARCIA RUBEN Aofficer: General Counsel | Buy | 40,000 | $0.33 |
| Dec 12, 2025 | GARCIA RUBEN Aofficer: General Counsel | Buy | 140,000 | $0.34 |
| Jun 12, 2025 | Niklas Victoria Ninon Oliviadirector | Grant | 22,000 | $0.87 |
Source: FBLG SEC Form 4 filings, latest Jun 23, 2026. For informational purposes only — not investment advice.
See the full FBLG insider & 13F page →FibroBiologics, Inc. Common Stock company profile
Overview
FibroBiologics, Inc. (NASDAQ:FBLG) is a clinical-stage biotechnology company founded in 2021 and headquartered in Houston, Texas. The company went public in February 2024 and focuses on developing innovative cell therapy treatments using fibroblasts, a type of connective tissue cell. As a pre-revenue biotech firm, FibroBiologics is currently advancing multiple therapeutic candidates through clinical trials, targeting conditions ranging from spinal disc degeneration to multiple sclerosis and cancer treatment.
Business
FibroBiologics operates in the cell therapy sector of biotechnology, which involves using living cells as therapeutic agents to treat diseases. The company specializes in fibroblast-based therapies, utilizing fibroblasts - cells that produce collagen and other proteins essential for tissue structure and wound healing - as the foundation for its treatments. The company's pipeline includes several therapeutic candidates at various stages of development. CybroCell represents the lead program, designed to treat degenerative disc disease, a common spinal condition that causes back pain and mobility issues. CYMS101 targets multiple sclerosis, an autoimmune disease affecting the central nervous system, while CYWC628 focuses on wound healing applications. In earlier-stage research, FibroBiologics is developing CYTER915, which aims to regenerate the thymus and spleen - organs critical for immune system function. CYPS317 targets psoriasis, a chronic skin condition, and TCB190 is being developed for certain cancer treatments. The company's approach leverages the natural regenerative properties of fibroblasts to potentially address tissue damage and disease across multiple therapeutic areas. As a clinical-stage company with no current revenue, all programs are in development phases, with the company focusing resources on advancing its most promising candidates through regulatory approval processes.
Revenue model
As a pre-revenue clinical-stage biotechnology company, FibroBiologics currently generates no income from product sales. The company operates on a research and development model funded primarily through equity financing, with the expectation of future revenue from successful therapeutic products. The company's future business model will likely center on product sales and licensing once therapies receive regulatory approval. Revenue streams may include direct sales of approved cell therapies to hospitals and clinics, licensing agreements with pharmaceutical partners for commercialization rights, and potential milestone payments during development partnerships. Several factors could significantly impact future profitability. Regulatory approval timelines represent the primary determinant of revenue generation, as clinical trials can take years and face high failure rates. Manufacturing costs for cell therapies are typically high due to complex production requirements and quality control standards. Competition from established pharmaceutical companies and other biotech firms developing similar treatments could affect market share and pricing power. Reimbursement policies from insurance providers and government healthcare programs will be crucial for commercial success, as cell therapies often carry premium pricing. The company's ability to demonstrate superior efficacy compared to existing treatments will determine market adoption rates. Additionally, intellectual property protection and the ability to scale manufacturing operations will influence long-term profitability margins.
Competitive moat
FibroBiologics operates in a highly competitive biotechnology landscape with limited sustainable competitive advantages at this early stage. The company's potential moat primarily relies on intellectual property protection around its fibroblast-based therapeutic approaches and any proprietary manufacturing processes it develops. The regulatory approval pathway could provide temporary competitive protection, as successful clinical trials and FDA approval create barriers for competitors seeking to enter the same therapeutic areas. However, this advantage is time-limited and subject to patent expiration. The company's focus on fibroblast-based therapies may offer some differentiation from competitors using other cell types or therapeutic approaches. Significant competitive threats come from well-funded pharmaceutical giants and established biotechnology companies with greater resources for research, clinical trials, and commercialization. Companies like Mesoblast, Athersys, and numerous others are developing competing cell therapy platforms. The cell therapy field attracts substantial investment, meaning new entrants with superior technology or funding could quickly erode any first-mover advantages. The company's moat appears relatively weak given its early-stage development, limited intellectual property portfolio, and the highly competitive nature of biotechnology innovation. Success will largely depend on clinical trial outcomes and the ability to demonstrate superior efficacy compared to existing and emerging treatments, rather than on sustainable structural advantages.
Risks & safety
FibroBiologics presents high financial risk typical of early-stage biotechnology companies with significant cash burn and no revenue generation. • Cash burn and solvency: The company burned approximately $5.3 million in Q1 2025, with $8.7 million in cash and short-term investments, providing roughly 1.5 years of runway at current burn rates • Debt levels: Debt-to-equity ratio of 0.54 indicates moderate leverage, though the company has negative shareholder equity • Current liquidity: Current ratio of 1.14 shows barely adequate short-term liquidity coverage • Valuation metrics: Price-to-book ratio of 14.0 appears elevated for a pre-revenue company, though meaningful valuation metrics are difficult to assess given negative earnings • Operating losses: Consistent negative EBITDA across all periods, with $4.5 million EBITDA loss in Q1 2025 • Dilution risk: As a cash-burning entity, the company will likely need additional equity financing, creating dilution risk for current shareholders The margin of safety is extremely limited, with the company facing potential funding needs within 12-18 months and high execution risk typical of clinical-stage biotechnology investments.
Recent development
Based on available financial data, FibroBiologics has been primarily focused on advancing its clinical pipeline since going public in February 2024. The company has maintained consistent research and development spending while managing cash resources carefully. The most significant development has been the company's transition to public markets, which provided access to capital markets for funding ongoing clinical trials. Financial data shows the company has been managing its cash burn rate, with quarterly operating cash flow losses ranging from $1.9 million to $5.3 million across recent periods. The company appears to have experienced some operational scaling challenges, evidenced by increasing cash burn rates in recent quarters. Q1 2025 showed elevated losses compared to prior periods, suggesting either increased clinical trial activity or higher operational costs as programs advance. Balance sheet management has been a key focus, with the company maintaining substantial cash reserves relative to its size, though these reserves are declining due to ongoing operations. The company's ability to advance multiple therapeutic candidates simultaneously suggests a strategic approach to portfolio development, though this also increases cash requirements and execution risk. Without detailed earnings call transcripts, specific strategic pivots or new product announcements cannot be identified, but the financial trajectory suggests continued focus on clinical development activities and careful capital allocation.
FBLG company profile · for informational purposes only — not investment advice.
Track FBLG with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free